Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein

A licensed vaccine for respiratory syncytial virus (RSV) is unavailable, and passive prophylaxis with the antibody palivizumab is restricted to high-risk infants. Recently isolated antibodies 5C4 and D25 are substantially more potent than palivizumab, and a derivative of D25 is in clinical trials. H...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Daiyin, Battles, Michael B., Moin, Syed M., Chen, Man, Modjarrad, Kayvon, Kumar, Azad, Kanekiyo, Masaru, Graepel, Kevin W., Taher, Noor M., Hotard, Anne L., Moore, Martin L., Zhao, Min, Zheng, Zi-Zheng, Xia, Ning-Shao, McLellan, Jason S., Graham, Barney S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707411/
https://www.ncbi.nlm.nih.gov/pubmed/29187732
http://dx.doi.org/10.1038/s41467-017-01858-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707411/
https://www.ncbi.nlm.nih.gov/pubmed/29187732
http://dx.doi.org/10.1038/s41467-017-01858-w

Ejemplares similares